ClinicalTrials.gg
CompletedNCT04161235Updated Nov 15, 2023

Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV

An observational study in Pulmonary Emphysema, sponsored by Pulmonx Corporation. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Pulmonx Corporation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Emphysema with a site in Germany — 3 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Emphysema · Germany.

Started
2020
the only one that year
Observational
6 of 14
none open now
Registered
11th of 14
by date
Lead sponsor
2 of 14
Pulmonx Corporation

Among the 14 studies in Pulmonary Emphysema with a site in Germany, this one is the only one that started in 2020, is one of 6 observational ones, and was the 11th registered.

Pulmonary Emphysema

64 studies on the registry are indexed under Pulmonary Emphysema; 7 are open to participants now.

Browse Pulmonary Emphysema studies →

Open to participants now

3 of the 14 studies in Pulmonary Emphysema with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 6 Pulmonary Emphysema studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Emphysema with a site in Germany, or all of them as a file.
02

Study summary

This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.

Read the detailed description

This is a multi-center, single-arm, prospective, observational study. Approximately 70 study participants undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV will be enrolled and followed out to 3 months. Assessments will be conducted at 45 days and 3 months. The evaluation will be conducted at up to 6 sites.

Patients prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after: 1) determination of little to no collateral ventilation between target and ipsilateral lobes and 2) implantation of at least one Zephyr Valve 5.5-LP EBV. Baseline data will be collected retrospectively after enrollment of a patient in the Post-Market Evaluation. Performance and safety of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP will be evaluated post-treatment based on data collected until 3 months after the treatment.

03

Conditions studied

  • Pulmonary Emphysema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population evaluated will comprise of patients with hyperinflation associated with severe emphysema that are considered appropriate for the procedure by their physician, confirmed to have little to no collateral ventilation and had at least one Zephyr Valve 5.5-LP EBV implanted during the procedure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with severe emphysema prescribed treatment with Zephyr Valves
  • Zephyr Valve Treatment with the use of at least one Zephyr Valve 5.5-LP EBV

Exclusion criteria

Exclusion Criteria:

  • Patients determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).
  • Patients who undergo Zephyr Valve treatment, but no Zephyr Valve 5.5-LP EBV implanted.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Treatment

    Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.

    Device: The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP

Interventions

  • DeviceThe Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP

    The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.

06

What researchers measure

Primary outcomes

  1. Treated Lobar Volume Reduction (TLVR) responders

    The percentage of patients treated with the Zephyr Valve 5.5-LP EBV who achieved a Treated Lobar Volume Reduction (TLVR) of the treated lobe (s) of ≥350ml as seen via HRCT at 45-days.

    Time frame: 45 days

Other outcomes

  1. Treated Lobar Volume Reduction (TLVR) changes from Baseline

    Treated Lobar Volume Reduction (TLVR) as seen via HRCT at 45-days (absolute and percent changes from baseline).

    Time frame: 45 days

  2. Lobar occlusion

    Lobar occlusion of the treated lobe at 45-days post-procedure as visualized by HRCT.

    Time frame: 45 days

  3. Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1)

    Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1) at 3-months (absolute and percent changes from baseline).

    Time frame: 3 months

  4. Residual Volume (RV)

    Residual Volume at 3 months, when available (absolute and percent changes from baseline).

    Time frame: 3 months

  5. Total Lung Capacity

    Total Lung Capacity (TLC) at 3 months, when available (absolute and percent changes from baseline).

    Time frame: 3 months

  6. Inspiratory Capacity

    Inspiratory Capacity (IC) at 3 months, when available (absolute and percent changes from baseline).

    Time frame: 3 months

  7. Residual Volume/Total Lung Capacity (RV/TLC)

    RV/TLC ratio at 3 months, when available (absolute and percent changes from baseline).

    Time frame: 3 months

  8. Inspiratory Capacity/Total Lung Capacity (IC/TLC)

    IC/TLC ratio at 3 months, when available (absolute and percent changes from baseline).

    Time frame: 3 months

07

Study locations

3 sites
  • Ruhrlandklinik Essen - Universitätsmedizin
    Essen, 45239, Germany
  • University Hospital of Zurich
    Zurich, 8091, Switzerland
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Aug 2021, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2019
First posted
Nov 13, 2019
StartActual
Feb 5, 2020
Primary completionActual
Aug 13, 2021
CompletionActual
Dec 30, 2021
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04161235
Lead sponsor
Pulmonx Corporation
Responsible party
Sponsor
First posted
Nov 13, 2019
Start date
Feb 5, 2020
Primary completion
Aug 13, 2021
Completion
Dec 30, 2021
Last update
Nov 15, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion